Vedolizumab as induction and maintenance therapy for ulcerative colitis
Abstract
Vedolizumab was more effective than placebo as induction and maintenance therapy for ulcerative colitis. (Funded by Millennium Pharmaceuticals; GEMINI 1 ClinicalTrials.gov number, NCT00783718.).
Keywords
National Center for Biotechnology Information
NCBI
NLM
MEDLINE
humans
pubmed abstract
nih
national institutes of health
national library of medicine
research support
non-u.s. gov't
adult
female
male
aged
middle aged
Drug Administration Schedule
Clinical Trial
Phase III
Randomized Controlled Trial
Antibodies
Monoclonal
Double-Blind Method
Multicenter Study
Brian G Feagan
Humanized / therapeutic use*
Colitis
Ulcerative / drug therapy*
drug therapy
combination
induction chemotherapy
immunosuppressive agents / therapeutic use
maintenance chemotherapy
glucocorticoids / therapeutic use
humanized / adverse effects
pmid:23964932
doi:10.1056/nejmoa1215734
paul rutgeerts
gemini 1 study group
humanized / pharmacokinetics
integrins / antagonists & inhibitors
integrins / immunology*
Access
Citation
ID:
117041
References
Blockchain Verification
Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
117041
Unique Identifier:
Network:
Scimatic Chain (ID: 481)
Loading...
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
Creates 1,000,000 NFT tokens for this article
Token Features:
- ERC-1155 Standard NFT
- 1 Million Supply per Article
- Transferable via MetaMask
- Permanent Blockchain Record
Scan with Saymatik Web3.0 Wallet
